| Q41130797 | Adequate thromboprophylaxis in critically ill patients |
| Q38261172 | Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much". |
| Q37867319 | Deep vein thrombosis and stress ulcer prophylaxis in the intensive care unit |
| Q35827649 | Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation |
| Q38107537 | Drug absorption, distribution, metabolism and excretion considerations in critically ill adults |
| Q33393101 | Enoxaparin and antifactor Xa levels in acute burn patients |
| Q50999671 | Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. |
| Q33389622 | Issues in assessing and reducing the risk for venous thromboembolism |
| Q38351793 | Pharmacokinetic considerations for drugs administered in the critically ill. |
| Q36510063 | Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children |
| Q37078508 | Platelets are dominant contributors to hypercoagulability after injury |
| Q53783646 | Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment? |
| Q30278059 | Portal vein thrombosis: When to treat and how? |
| Q37518149 | Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis |
| Q37831720 | Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients |
| Q26797444 | Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis |